U
UPEXI, INC.
Period
FY 2025
Revenue
$15.81M
Net Income
$-13.68M
Total Assets
$123.81M
Equity
$90.10M
Shares Out
70.26M
Op. Cash Flow
$-8.42M
Business
Upexi, Inc. is a dual-focus company combining a cryptocurrency treasury strategy with consumer product brand ownership. Its primary activity is holding and staking Solana tokens in a digital asset treasury, delegated to third-party validators for yield generation. Secondarily, it owns and operates several consumer brands—LuckyTail (pet care), PRAX (energy drinks), Cure Mushrooms (functional mushrooms), Moonwalkr (cannabinoid products), and Gumi Labs (gummy manufacturing)—distributed through direct-to-consumer channels, Amazon, and wholesale partnerships, supported by Upexi Distribution warehousing and fulfillment services.
Summary from 10-K filed 2025-09-24
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Revenue | 15 | 26 | — | — | — | |
| Digital asset revenue | 985,009 | 0 | — | — | — | |
| Total revenue | 16 | 26 | 36 | 23 | 24 | |
| Cost of revenue | 5 | 13 | 15 | 8 | 12 | |
| Gross profit | 11 | 13 | 21 | 15 | 12 | |
| Sales and marketing | 4 | 6 | 6 | 5 | 2 | |
| Distribution costs | 5 | 9 | 9 | 2 | — | |
| General and administrative expenses | 12 | 7 | 7 | 9 | 6 | |
| Realized and unrealized (gain) loss on digital assets | −105,474 | 0 | — | — | — | |
| Share-based compensation | 2 | 1 | — | 3 | 611,432 | |
| Amortization of acquired intangible assets | 76,758 | 2 | 3 | 979,988 | 726,525 | |
| Depreciation | 681,000 | 1 | 913,246 | 574,309 | 303,496 | |
| Impairment of long-lived asset - building | 0 | 336,434 | 0 | — | — | |
| Loss on the sale / abandonment of assets in relocation | 0 | 569,195 | 0 | — | — | |
| Impairment of intangible assets and goodwill | 0 | 8 | — | — | — | |
| Lease impairment (gain on settlement), Delray Beach facility | −269,994 | 289,969 | — | — | — | |
| Operating expenses | 23 | 35 | 33 | 21 | 10 | |
| Loss from operations | −12 | −22 | −12 | −6 | 1 | |
| Other | −10,743 | −16,443 | −5 | 101,082 | −269,396 | |
| Interest (expense) income, net | −1 | −3 | −5 | −202,120 | 530,449 | |
| Other income (expense), net | −1 | −3 | — | — | — | |
| Loss on operations before income tax | −14 | −26 | −17 | −6 | — | |
| Income tax benefit (expense) | 0 | 332,101 | 3 | — | — | |
| Total income tax expense benefit | 0 | 332,101 | 3 | 518,398 | 1 | |
| Net loss from continuing operations | −14 | −25 | −14 | −6 | — | |
| Interactive Offers | 0 | 237,670 | 0 | — | — | |
| VitaMedica | 0 | 2 | 0 | — | — | |
| E-core | 0 | −2 | 0 | — | — | |
| Gain (loss) from the sale of total | 0 | 448,882 | — | — | — | |
| Infusionz | — | 71,976 | −338,418 | — | — | |
| Interactive Offers | 0 | −187,003 | −2 | — | — | |
| VitaMedica | 0 | 213,636 | −382,449 | — | — | |
| E-core | 0 | 1 | 1 | — | — | |
| Income (loss) income from discontinued operations | 0 | 1 | −1 | −1 | — | |
| Net income (loss) attributable to Upexi, Inc. | −14 | −24 | — | −2 | 3 | |
| Income (loss) per share from continuing operations | −1.73 | −24.6 | −15.56 | −0.36 | — | |
| (Loss) income per share from discontinued operations | 0 | 1.13 | −1.53 | 5 | — | |
| Total income (loss) per share attributable to Upexi shareholders | −1.73 | −23.03 | −18.94 | −0.43 | 0.25 | |
| Income (loss) per share from continuing operations | −1.73 | −24.6 | −15.56 | −0.07 | — | |
| (Loss) income per share from discontinued operations | 0 | 1.13 | −1.53 | −0.36 | — | |
| Total income (loss) per share attributable to Upexi shareholders | −1.73 | −23.03 | −18.94 | −0.43 | 0.21 | |
| Basic weighted average shares outstanding | 8 | 1 | 893,943 | 16 | 12 | |
| Fully diluted weighted average shares outstanding | 8 | 1 | 893,943 | 16 | 14 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Cash | 3 | 661,415 | 4 | 7 | — | |
| Accounts receivable, net | 157,515 | 606,885 | 1 | 939,875 | 1 | |
| Inventory, net | 1 | 1 | 5 | 5 | 2 | |
| Due from VitaMedica transition | 228,017 | 212,358 | — | — | — | |
| Prepaid expenses and other receivables | 350,836 | 502,188 | 1 | 760,900 | 386,258 | |
| Current digital assets at fair value | 50 | 0 | — | — | — | |
| Assets available for sale - Building | 0 | 4 | 5 | — | — | |
| Purchase price receivable - VitaMedica | 2 | 2 | 0 | — | — | |
| Purchase price receivable - E-core | 0 | 2 | 0 | — | — | |
| Total current assets | 57 | 11 | 30 | 17 | 18 | |
| Property and equipment, net | 2 | 2 | 3 | 7 | 3 | |
| Intangible assets, net | 163,113 | 239,871 | 7 | 9 | 2 | |
| Goodwill | 848,854 | 848,854 | 3 | 5 | 2 | |
| Deferred tax asset | 6 | 6 | 6 | — | — | |
| Digital assets at fair value, net of current | 56 | 0 | — | — | — | |
| Other assets | 192,123 | 278,435 | 76,728 | 75,613 | 49,068 | |
| Right-of-use asset, net | 2 | 2 | 410,453 | 844,856 | 417,443 | |
| Total other assets | 67 | 12 | 34 | 31 | 9 | |
| Total assets | 124 | 24 | 64 | 48 | 27 | |
| Accounts payable | 1 | 481,647 | 1 | 2 | 2 | |
| Accrued compensation | 3 | 1 | 533,842 | 489,712 | 1 | |
| Deferred revenue | 13,155 | 235,255 | 0 | 335,205 | 485,973 | |
| Accrued liabilities | 356,064 | 736,407 | 2 | 816,632 | 296,021 | |
| Accrued interest | 792,449 | 476,018 | 655,187 | — | — | |
| Acquisition payable | 260,652 | 413,152 | — | — | — | |
| Related party advances, net | 0 | 100,000 | — | — | — | |
| Current portion of note payable | 560,000 | 0 | 338,474 | 749,752 | 447,100 | |
| Short-term treasury debt | 20 | 0 | — | — | — | |
| Current portion of Cygnet subsidiary notes payable | 5 | 5 | 795,778 | — | — | |
| Note payable on building for sale | 0 | 3 | — | — | — | |
| Current portion of operating lease payable | 691,010 | 1 | 454,127 | 183,881 | 199,532 | |
| Total current liabilities | 33 | 13 | 22 | 10 | 6 | |
| Operating lease payable, net of current portion | 1 | 2 | 0 | 700,411 | 217,430 | |
| Related party note payable | 0 | 500,000 | — | — | — | |
| Note payable | 0 | 557,429 | 5 | — | — | |
| Convertible notes payable | 0 | 2 | 0 | 3 | — | |
| Total long-term liabilities | 1 | 4 | 14 | 10 | 217,430 | |
| Preferred stock, $0.00001 par value, 10,000,000 shares authorized, and 150,000 and 25,000 shares issued and outstanding, respectively | 2 | 1 | 25 | 500 | 500 | |
| Common stock, $0.00001 par value, 300,000,000 shares authorized, and 38,270,571 and 1,045,429 shares issued and outstanding, respectively | 383 | 11 | 20,216 | 16,713 | 15,262 | |
| Additional paid in capital | 151 | 53 | 52 | 35 | 25 | |
| Accumulated deficit | −61 | −47 | −23 | −6 | −4 | |
| Total stockholders' equity attributable to Upexi, Inc. | 90 | 7 | 28 | 29 | 21 | |
| Total stockholders' equity | 90 | 7 | 28 | 29 | 21 | |
| Total liabilities and stockholders' equity | 124 | 24 | 64 | 48 | 27 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-06-30 | FY 2024 2024-06-30 | FY 2023 2023-06-30 | FY 2022 2022-06-30 | FY 2021 2021-06-30 |
|---|---|---|---|---|---|---|
| Net loss from operations | −14 | −24 | −17 | −2 | — | |
| Depreciation and amortization | 757,758 | 4 | 3 | 3 | 1 | |
| Unrealized (gain) loss on digital assets | −101,332 | 0 | — | — | — | |
| Gain on the sale of VitaMedica and income from discontinued operations | 0 | −2 | 0 | — | — | |
| Loss on the sale of New England Technology | 0 | 2 | 0 | — | — | |
| Amortization of loan costs | 30,462 | 115,787 | — | — | — | |
| Amortization of consideration discount | 0 | 1 | 969,098 | 0 | — | |
| Inventory write-offs | 748,874 | 2 | 118,990 | 1 | 375,000 | |
| Loss on sale of assets related to relocation of facility | 0 | 569,195 | — | — | — | |
| Gain on sale of interactive offers | 0 | −237,670 | 0 | — | — | |
| Loss on the disposal of assets | 10,743 | 0 | — | — | — | |
| Bad debt reserve for Amazon receivable | 933,950 | 0 | 0 | 131,968 | — | |
| Reduction of acquisition payable | −152,500 | 0 | — | — | — | |
| Issuance of stock for services | 250,000 | 0 | 0 | 576,774 | — | |
| Lease impairment (gain on settlement) | −269,994 | 0 | — | — | — | |
| Change in deferred tax asset | 0 | −344,802 | — | — | — | |
| Stock based compensation | 2 | 1 | — | 3 | 611,432 | |
| Accounts receivable | −484,580 | 675,709 | −364,665 | 284,998 | −1 | |
| Inventory | −470,188 | 3 | −1 | −3 | −846,659 | |
| Prepaid expenses and other assets | 222,005 | 106,611 | 287,797 | 284,653 | −313,206 | |
| Operating lease payable | 20,965 | 302,050 | 4,238 | 37,922 | — | |
| Accounts payable and accrued liabilities | 3 | −944,020 | 389,458 | −446,609 | — | |
| Deferred revenue | −222,100 | 101,305 | 0 | −478,385 | −99,770 | |
| Net cash provided by operating activities - Continuing Operations | −8 | −5 | −7 | 715,150 | — | |
| Net cash provided by (used in) operating activities - Discontinued Operations | 0 | 5 | 8 | −895,981 | — | |
| Net cash provided by operating activities | −8 | −101,376 | 202,677 | −180,831 | 3 | |
| Proceeds from the sale of the building, net | 4 | 0 | — | — | — | |
| Proceeds from the sale of VitaMedica, Inc. | 0 | 2 | — | — | — | |
| Proceeds from the sale of E-core | 2 | 0 | — | — | — | |
| Proceeds from the sale of Interactive Offers, net of liabilities paid | 0 | 203,025 | 0 | — | — | |
| Acquisition and sale of digital assets, net | −105 | 0 | — | — | — | |
| Acquisition of Cygnet Online LLC, net | 0 | −539,348 | −500,000 | −3 | — | |
| Acquisition of property and equipment | −387,760 | −932,565 | −937,564 | −5 | −1 | |
| Net cash provided by (used in) investing activities - Continuing Operations | −99 | 831,112 | −23,271 | −11 | — | |
| Net cash (used in) investing activities - Discontinued Operations | 0 | −4 | −3 | 0 | — | |
| Net cash provided by (used in) investing activities | −99 | −3 | −3 | −11 | −1 | |
| Payment on acquisition notes payable | −66,655 | −246,761 | — | — | — | |
| Payment on convertible note | −150,000 | 0 | −6 | 0 | — | |
| Proceeds from issuance of short-term debt | 20 | 0 | — | — | — | |
| Proceeds from warrant exercise | 250,000 | 0 | — | — | — | |
| Proceeds from issuance of stock | 93 | 0 | — | 0 | 11 | |
| Issuance of preferred stock series A | 325,000 | 0 | — | — | — | |
| Repayment of related party advance | −175,000 | 0 | — | 0 | −750,000 | |
| Proceeds from related party advance | 75,000 | 100,000 | 0 | 0 | — | |
| Proceeds from issuance of convertible notes | 350,000 | 0 | 3 | — | — | |
| Repayment of related party note payable | −500,000 | 0 | −445,670 | −1 | −12,000 | |
| Repayment on note payable on building | −3 | −207,028 | — | — | — | |
| Net cash used in financing activities - Continuing Operations | 110 | −353,789 | 6 | 4 | — | |
| Net cash (used in) provided by financing activities - Discontinued Operations | 0 | 0 | −6 | 0 | — | |
| Net cash used in financing activities | 110 | −353,789 | −285,333 | 4 | 12 | |
| Net increase (decrease) in cash - Continuing Operations | 2 | −4 | — | −7 | 14 | |
| Net (decrease) increase in cash - Discontinued Operations | 0 | 586,551 | — | — | — | |
| Interest paid | 805,880 | 839,000 | 2 | 64,460 | — | |
| Income tax paid | 0 | 0 | 0 | 656,000 | — | |
| Issuance of common stock for acquisition of Cygnet | 0 | 162,727 | — | — | — | |
| Non-cash proceeds in the sale of VitaMedica | 0 | 2 | — | — | — | |
| Issuance of common stock for the repayment of convertible notes payable | 2 | 500,000 | 0 | — | — | |
| Issuance of debt for acquisition of Cygnet | 0 | 300,000 | — | — | — | |
| Bloomios non-cash payment of receivables, net | 0 | 845,443 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is UPEXI, INC.'s CIK number?
UPEXI, INC.'s SEC CIK number is 0001775194 (1775194). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find UPEXI, INC.'s SEC filings?
All of UPEXI, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did UPEXI, INC. last report earnings?
UPEXI, INC. (UPXI) most recently filed an earnings 8-K with the SEC on May 13, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001477932-26-003058). This is UPEXI, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is UPEXI, INC.'s most recent earnings 8-K?
UPEXI, INC.'s latest earnings 8-K (Item 2.02) was filed May 13, 2026 under accession 0001477932-26-003058. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View UPEXI, INC.'s latest earnings 8-K →
Look up any company's CIK number →